Patents by Inventor Isaiah J. Fidler

Isaiah J. Fidler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160025728
    Abstract: The present disclosure provides a method of detecting and diagnosing metastatic spread of cancer to the brain by analyzing the product of a gene signature. Gene signatures detailed herein are specific to the brain metastasis and not dependent upon the genetic signature of the primary tumor. Accordingly, disclosed method can be used to guide therapeutic intervention and further diagnostic analysis.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Isaiah J. FIDLER, Sun Jin KIM
  • Publication number: 20150182583
    Abstract: Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothclin receptor A (ETA) and endothelin receptor B (ETB) may be administered to a subject to reduce tau production or accumulation, e.g., in astrocytes. The antagonist may be a dual ETA and ETB receptor antagonist. In some aspects, methods are provided for the treatment of chemo-brain, hypoxia, brain ischemia, surgical dementia, glioblastoma, or a traumatic brain injury (TBI).
    Type: Application
    Filed: August 6, 2013
    Publication date: July 2, 2015
    Applicant: Board Of Regents, The University Of Texas System
    Inventor: Isaiah J. Fidler
  • Publication number: 20120144510
    Abstract: The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.
    Type: Application
    Filed: August 9, 2010
    Publication date: June 7, 2012
    Applicant: Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Sun-Jin Kim
  • Patent number: 7344829
    Abstract: Methods for determining the effectiveness of anticancer agents by determining and comparing growth factor receptor phosphorylation levels in samples obtained by non-invasive procedures before and after anticancer treatments are provided. The invention also provides methods for detecting growth factor receptor phosphorylation in hair follicles and other tissues obtained by non-invasive means.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: March 18, 2008
    Assignee: Board of Regents, the University of Texas System
    Inventors: Isaiah J. Fidler, Corazon D. Bucana
  • Patent number: 6872385
    Abstract: Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells. The claimed compositions and methods are particularly relevant in anti-tumor and cancer therapy. Of specific interest is the ability of the compositions of the invention to elicit a response that controls not only the primary tumor but also any metastatic cells or metastatic tumors which subsequently arise.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: March 29, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Zhongyun Dong, Weixin Lu
  • Publication number: 20030206890
    Abstract: Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells. The claimed compositions and methods are particularly relevant in anti-tumor and cancer therapy. Of specific interest is the ability of the compositions of the invention to elicit a response that controls not only the primary tumor but also any metastatic cells or metastatic tumors which subsequently arise.
    Type: Application
    Filed: May 31, 2001
    Publication date: November 6, 2003
    Inventors: Isaiah J. Fidler, Zhongyun Dong, Weixin Lu
  • Publication number: 20020132275
    Abstract: Methods for determining the effectiveness of anticancer agents by determining and comparing growth factor receptor phosphorylation levels in samples obtained by non-invasive procedures before and after anticancer treatments are provided. The invention also provides methods for detecting growth factor receptor phosphorylation in hair follicles and other tissues obtained by non-invasive means.
    Type: Application
    Filed: November 2, 2001
    Publication date: September 19, 2002
    Applicant: Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Corazon D. Bucana
  • Patent number: 6342216
    Abstract: Provided are compositions and methods of use for insect cells comprising baculovirus encoding non-surface expressed proteins and peptides. The claimed invention particularly relates to compositions comprising insect cells containing baculovirus that express cytokines. Such compositions may be administered by, for example, direct intratumoral injection into tumors in mammals, resulting in tumor reduction or recission. Another aspect of the claimed invention concerns methods of promoting resistance to the reoccurence of tumors in mammals who have undergone such tumor recission. In a specific aspect of the claimed invention, the mammals are human subjects presenting with various forms of cancer.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: January 29, 2002
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Zhongyun Dhong, Weixin Lu
  • Patent number: 4916118
    Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate chemotactic peptides such as N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes stimulate macrophage activity which is especially useful in the cancer therapy for combating metastatic tumor cells and for treatment of chronic infections.
    Type: Grant
    Filed: August 12, 1987
    Date of Patent: April 10, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: Isaiah J. Fidler, Kiyoshi Morikawa, Rajiv Nayar
  • Patent number: 4774085
    Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate water soluble muramyldipeptide derivatives in combination with gamma-interferon. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes are especially useful in the cancer chemotherapy for combating metastatic tumor cells.
    Type: Grant
    Filed: July 9, 1985
    Date of Patent: September 27, 1988
    Assignee: 501 Board of Regents, Univ. of Texas
    Inventor: Isaiah J. Fidler
  • Patent number: 4571332
    Abstract: N-(3-(3-.sup.125 iodo, 4-hydroxybenzyl)propionyl)phosphatidylethanolamine[.sup.125 I-phenylpropionyl-PE], a nonexchangeable iodinated lipid of high specific radioactivity is disclosed, with a method for its synthesis as well as the synthesis of other iodinated lipids using a technique involving acylation of the amine nitrogen of a phospholipid, such as phosphatidylethanolamine, with an [.sup.125 I] or [.sup.131 I] substituted cyclic organic acid, for example, monoiodinated Bolton-Hunter reagent and purification by thin layer chromatography. The iodinated lipid may be quantitatively incorporated into vesicles for use as an accurate liposome tracer in in vitro and in vivo assays that require high levels of sensitivity unobtainable with most other lipid-labeling techniques.
    Type: Grant
    Filed: September 19, 1982
    Date of Patent: February 18, 1986
    Assignee: Litton Bionetics, Inc.
    Inventors: Alan J. Schroit, Isaiah J. Fidler